Since its inception in 1993, the McDonnell Genome Institute has played a vital role in genomics, receiving over $1.3 billion in research funding.
Research from the institute is published in the world’s top scientific journals, including Nature, Science and the New England Journal of Medicine.
From contributing 25% of the finished sequence to the Human Genome Project to sequencing the first cancer genome, up to today’s innovative COVID-19 testing, MGI’s research continues to advance the diagnosis, treatment, and prevention of disease.
Today we build on this knowledge and work with our collaborators to build an entire genomic picture. This includes the services from groups, such as GTAC@MGI and GEiC@MGI to understand the functional aspects of the genetic code.
The role that I think the Genome Institute will play over the next decade will be to devise rapid and efficient ways to separate the genomic wheat from the chaff, so to speak. We want to identify those DNA variations that are crucial to the disease process, so we can develop better treatments. With that in mind, I see the McDonnell Genome Institute serving as a hub for precision medicine at Washington UniversityDr. Jeffrey Milbrandt
Here is a description of the most recent lab process we developed in the fight against COVID-19.